Shots:

• The first patient has been enrolled in P-IIb (IASOS) study to evaluate orismilast (PO) vs PBO in 200 patients with mod. to sev. psoriasis who will be randomized to 3 active doses at 40 centers in the EU & North America
• The primary objective of the study is to evaluate the efficacy & safety of a modified release orismilast tablet compared to PBO while the purpose of the study is to identify the dose-regimen for P-III studies with orismilast in psoriasis
• Orismilast is a next-generation PDE4 inhibitor with broad anti-inflammatory properties & has received FTD from the US FDA for the treatment of mod. to sev. AD in Nov 2021. The therapy is currently under development for the treatment of HS and AD

Ref: PR Newswire | Image: Union